Bringing the fundamentals into focus…
Back to Phathom Pharmaceuticals, Inc.
How Phathom Pharmaceuticals, Inc. stacks up
PHAT · against 1,335 other Healthcare companies
Profitability
29/ 100
Below the middle of the pack.
Ranked #943 of 1,336 · scores higher than 29% of peers
Bars: peers in each 10-point band of the profitability score133 peers with a profitability score of 20–29, including PHAT · Click a bar to see the companies
Why profitability scores 29?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on invested capital and operating margin, which are weaker than most Healthcare peers.
- a lower return on invested capital: weaker than 87% of peers. Return on invested capital: -46.6% vs peer median 4.7%
- a thinner operating margin: weaker than 77% of peers. Operating margin: -17.0% vs peer median 7.1%
- a higher return on assets: stronger than 99% of peers. Return on assets: 37.3% vs peer median 1.7%
Metric by metric
Position: dot = PHAT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PHAT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 1,226 reported | -46.6% | 4.7% | 13% | 33% | |
| Operating marginHigher is better · 1,251 reported | -17.0% | 7.1% | 23% | 33% | |
| Return on assetsHigher is better · 1,315 reported | 37.3% | 1.7% | 99% | 33% | |
| Return on equityHigher is better · 1,252 reported | Not reported | 3.2% | — | — | Context only |
| Gross marginHigher is better · 1,394 reported | 82.9% | 45.9% | 90% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around PHAT| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 5 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 943 | 82M USD | 29 | 27 | |
| 943 | 2.9B USD | 29 | 44 | |
| 943 | 487M USD | 29 | 29 | |
| 943 | 1.8B USD | 29 | 31 | |
| 943 | 464M USD | 29 | 53 | |
| 956 | 2.7B CNY (≈$383M) | 28 | 24 | |
| 956 | 172.4B KRW (≈$124M) | 28 | 26 | |
| 956 | 15.4B HKD (≈$2.0B) | 28 | 44 | |
| 956 | 4.7B CNY (≈$661M) | 28 | 26 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score